

Southern California Psychiatric Society
**Psychopharmacology
Update 21**
Saturday, January 30, 2010
The Olympic Collection

Please Print

Name: _____

Address: _____

City/State/Zip: _____

		# Attending
SCPS Member	\$150	_____
Non-SCPS Member	\$175	_____
SCPS Resident *	\$10	_____
Non-SCPS Resident *	\$20	_____
Total enclosed:		_____

**Must be enrolled in a full-time, degree granting program. Must send photocopy of student I.D. with registration form. NO EXCEPTIONS.*

Please make check payable to SCPS and mail w/ this registration form to: **SCPS, 2999 Overland Av., #208, Los Angeles, CA 90064.**

Cancellations must be received 48 hours prior to the meeting and will be assessed a \$45 administrative processing fee.


The Southern California Psychiatric Society presents

Psychopharmacology Update 21

Saturday, January 30th, 2010

**The Olympic Collection
11301 Olympic Blvd.
Los Angeles, CA 90064
310.575.4585**

For psychiatrists and all physicians interested in psychopharmacology



Psychopharmacology Update 21

8:30 a.m. - Registration , Continental Breakfast, Booth Exhibits

8:55 a.m - Opening Remarks

9:00 a.m. - Generic Drugs: Good Values or Bad Bargains?
James W. Jefferson, MD, Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health and Distinguished Senior Scientist Madison Institute of Medicine.

The Federal Drug Price Competition and Patent Term Restoration Act of 1984 opened the floodgates to generic drugs by removing requirements for independently establishing efficacy and safety, and by basing approval on bioequivalence. The process required to establish bioequivalence will be discussed, as well as related relevant terms and concepts. The pros and cons of generic prescribing will be discussed and illustrated by examples involving antidepressants.

10:00 a.m. - Managing Depression During Pregnancy: Latest Consensus Findings and Guidelines
Vivien K. Burt, M.D., Professor Emeritus of Psychiatry, UCLA; Founder/Director, The Women's Life Center, UCLA.
Between 14% and 23% of pregnant women will experience a depressive disorder while pregnant. In 2003, about 13% of women took an antidepressant at some point during pregnancy, double the rate since 1999. In order to provide full and comprehensive care that maximizes safety for mothers and their babies, it is thus relevant and important for clinicians to know and understand the information on the treatment of perinatal depression. The latest literature on fetal and neonatal outcomes associated with depression and antidepressant treatment during pregnancy will be reviewed. Research findings, guidelines and algorithms for preconception and antenatal management will be presented and discussed.

11:00 a.m. - Break

11:15 a.m. - An Evidence Based "How to Guide" for Antidepressant Augmentation Strategies *David Fogelson, M.D., Clinical Professor of Psychiatry, UCLA Department of Psychiatry and Biobehavioral Sciences.*
When a patient does not respond to an adequate trial of an antidepressant, how do you decide what to use for augmentation? What do the most current treatment algorithms recommend? We will review combinations of antidepressants, buspirone, T3, lithium, lamotrigine, atypical antipsychotics, pindolol, psychostimulants, nutraceuticals, benzodiazepines, and psychotherapy as strategies for antidepressant augmentation.

12:15 p.m. - Lunch (lunch will not be provided)

1:30 p.m. - Problematic Hypersexuality: Diagnosis and Treatment *John Sealy, M.D., Assistant Clinical Professor of Psychiatry UCLA School of Medicine.*

Problematic hypersexuality, often referred to as sexual addiction, is an increasingly common behavior complaint across a broad age span. Although this disorder remains on the frontier of psychiatry, guidelines for diagnosis, comorbidities, consequences and treatment will be discussed to help clinicians make effective interventions.

2:30 p.m. - Performance Enhancing Drugs: from High School to the Olympic Games *Don H. Catlin, M.D., UCLA Professor of Molecular and Medical Pharmacology, Emeritus CEO, Anti-Doping Research*

Sport has been coping with drugs and sport for fifty years. The presentation will explain the type of drugs that are used, and comment on questions such as: How pervasive are they? Do they really enhance performance? Why do athletes continue to use them? How effective are the testing schemes? The presentation will also offer a brief overview of the use of performance enhancing drugs in school and the work place as well as reflection on the social and cultural implications of performance enhancing drugs in general.

Questions? Call (310) 815-3650

Continuing Education

The Southern California Psychiatric Society is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. The Southern California Psychiatric Society takes responsibility for the content, quality and scientific integrity of this CME activity.



The Southern California Psychiatric Society designates this educational activity for a maximum of 5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

Overview

SCPS is pleased to present a distinguished panel of experts to address topics of practical importance for clinical practice.

The program begins with a perspective on generic drugs and the pros and cons of generic prescribing. Next we will have a presentation on the latest consensus findings and guidelines for managing depression during pregnancy. Our third presentation provides an evidence-based guide for anti-depressant augmentation strategies. Following lunch there will be an overview of diagnosis and treatment of problematic hypersexuality, which is often referred to as sexual addiction. The final presentation of the day will explore many facets of the use of performance enhancing drugs in school, the work place, and sports.

Objectives:

At the end of this seminar, participants will have:

- 1) Understanding of the background of generic drugs and the pros and cons of prescribing them.
- 2) Familiarity with the latest consensus findings and guidelines for the management of depression during pregnancy.
- 3) Familiarity with evidence-based strategies for the augmentation of anti-depressant treatment.
- 4) Knowledge relevant to improved diagnosis and treatment of problematic hypersexuality.
- 5) Understanding of the principles relevant to the use of performance enhancing drugs in school, the work place and sport.

SCPS would like to thank: *Michael Gales, M.D. (Program Chair), William Arroyo, M.D., Jacquelyn Green, M.D., Heather Silverman, M.D., and Harvey Sternbach, M.D.* for planning this event.